<DOC>
	<DOCNO>NCT02038153</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose lenalidomide well work treat old patient acute myeloid leukemia undergone stem cell transplant . Biological therapy , lenalidomide , may stimulate immune system different way stop cancer cell grow .</brief_summary>
	<brief_title>Lenalidomide Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine safety efficacy maintenance lenalidomide post autologous peripheral blood stem cell transplantation ( PBSCT ) elderly patient acute myeloid leukemia ( AML ) . SECONDARY OBJECTIVES : I . To define maximum tolerate dose ( MTD ) establish therapeutic dose level ( TDL ) lenalidomide give post autologous transplant AML . II . To determine progression free survival patient treat approach . III . To determine overall survival patient treat approach . IV . To determine role residual AML stem cell efficacy lenalidomide maintenance autologous PBSCT . OUTLINE : This phase I , dose-escalation study follow phase II study . Patients receive lenalidomide orally ( PO ) daily ( QD ) day 1-21 . Courses repeat 4 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day every 6 month thereafter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients must confirm diagnosis nonM3 AML ; antecedent myelodysplastic syndrome ( MDS ) acceptable Post autologous stem cell transplant bone marrow biopsy core consistent morphologic remission Must receive induction consolidation chemotherapy , autologous stem cell transplant AML Life expectancy great 12 month Karnofsky performance status 70 great Leukocytes &gt; = 2,000/mcL Absolute neutrophil count &gt; = 1,000/mcL Platelets &gt; = 75,000/mcL Total bilirubin = &lt; 4 X institutional upper limit normal unless 2nd Gilbert 's disease Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 4 X institutional upper limit normal Creatinine &lt; 1.5 X institutional upper limit normal OR creatinine clearance &gt; = 30 mL/min/1.73 m^2 patient creatinine level institutional normal Able take aspirin , warfarin , low molecular weight heparin prophylactic anticoagulation Ability understand willingness sign write informed consent document Must register mandatory RevAssist® program willing able comply requirement RevAssist® Patient receive chemotherapy radiotherapy within 2 week prior enter study recover adverse event due agent administer 4 week earlier Patient receive another investigational agent post autologous stem cell transplant Patient receive another investigational product study Patient growth factor transfusion dependent Patient central nervous system ( CNS ) leukemia History allergic reaction attribute thalidomide lenalidomide History erythema nodosum , characterize desquamate rash take thalidomide similar drug Prior malignancy except resect basal cell carcinoma treat cervical carcinoma situ ; cancer treat curative intent &lt; 5 year Uncontrolled illness include , limited ongoing active infection , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ; patient must suffer recent ( &lt; 6 month ) myocardial infarction , unstable angina , uncontrolled hypertension , difficult control cardiac arrhythmia Evidence uncontrolled congestive heart failure ( CHF ) Active hepatitis B define hepatitis B surface antigen positivity , unless able start dual antihepatitis B ( HepB ) therapy , already dual antiHepB therapy Patients positive hepatitis B core antibody , negative hepatitis B surface antigen , lamivudine 100 mg daily least 3 month posttransplant Patient positive human immunodeficiency virus ( HIV ) human Tcell lymphotropic virus ( HTLV ) 1 Women childbearing potential ( define sexually mature woman undergone hysterectomy menses time precede 24 consecutive month ) Men agree father child refuse use latex condom sexual contact woman childbearing potential take lenalidomide 4 week therapy stop , even undergone successful vasectomy</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>